BEHAVIORAL SCREENING FOR COGNITION ENHANCERS - FROM INDISCRIMINATE TO VALID TESTING .1.

被引:137
作者
SARTER, M
HAGAN, J
DUDCHENKO, P
机构
[1] Department of Psychology, The Ohio State University, Columbus, 43210, OH
关键词
NOOTROPICS; COGNITION ENHANCERS; DEMENTIA; AGING;
D O I
10.1007/BF02245132
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Preclinical efforts to detect and characterize potential cognition enhancers appear to have been dominated by a strategy of demonstrating a wide variety of apparently beneficial behavioral effects with little attention given to the specific psychological mechanisms underlying behavioral enhancement. In particular, the question of whether or not behavioral facilitation is based on relevant mnemonic mechanisms and is independent of the stimulus properties and/or the motivational and attentional components of a task is not often considered. As a result, an overwhelming number of compounds have failed to produce the clinical effects predicted for them on the basis of preclinical research. The available data suggest that a more successful approach requires deductive research strategies rather than the indiscriminate accumulation of apparently beneficial effects in a variety of behavioral tasks and animal models. The first step towards such an approach is a systematic and rigorous evaluation of the different aspects of validity for the models most frequently used in preclinical research. It is concluded that a combination of good construct validity and good face validity represents a necessary condition for screening tests with predictive validity, and that the most popular paradigms fail to fulfil these criteria. Future screening programs for cognition enhancers will probably be characterized by a depreciation of "fast and dirty tests" in favor of approaches focussing on the validity of the effects of potential cognition enhancers.
引用
收藏
页码:144 / 159
页数:16
相关论文
共 171 条
[1]  
BAGNE CA, 1986, TREATMENT DEV STRATE, P585
[2]   TREATMENT OF ALCOHOL ORGANIC MENTAL DISORDER WITH PIRACETAM [J].
BARNAS, C ;
MILLER, C ;
GUNTHER, V ;
FLEISCHHACKER, WW .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1987, 11 (06) :729-737
[3]   THE EFFECTS OF ONDANSETRON, A 5-HT3 RECEPTOR ANTAGONIST, ON COGNITION IN RODENTS AND PRIMATES [J].
BARNES, JM ;
COSTALL, B ;
COUGHLAN, J ;
DOMENEY, AM ;
GERRARD, PA ;
KELLY, ME ;
NAYLOR, RJ ;
ONAIVI, ES ;
TOMKINS, DM ;
TYERS, MB .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 35 (04) :955-962
[4]  
BARONDES SH, 1969, INT REV NEUROBIOL, V12, P177
[5]  
BARRACO RA, 1976, PSYCHOL BULL, V2, P242
[6]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[9]   PATTERNS OF MEMORY FAILURE AFTER SCOPOLAMINE TREATMENT - IMPLICATIONS FOR CHOLINERGIC HYPOTHESES OF DEMENTIA [J].
BEATTY, WW ;
BUTTERS, N ;
JANOWSKY, DS .
BEHAVIORAL AND NEURAL BIOLOGY, 1986, 45 (02) :196-211
[10]   MECHANISMS OF CHOLINESTERASE INHIBITION IN SENILE DEMENTIA OF THE ALZHEIMER TYPE - CLINICAL, PHARMACOLOGICAL, AND THERAPEUTIC ASPECTS [J].
BECKER, RE ;
GIACOBINI, E .
DRUG DEVELOPMENT RESEARCH, 1988, 12 (3-4) :163-195